Nonsteroidal anti-inflammatory drug sulindac sulfide (sulindac) could inhibit colon cancer growth and metastasis by manipulation of the β-catenin signaling through reduction of S100A4 expression. Here, S100A4 is linked to malignant colon neoplasm.